UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/400/0.1/18.09.24

UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/400/0.1/18.09.24 Stock

DE000HC9M0Y2

Real-time BOERSE MUENCHEN 15:40:46 2024-06-28 EDT
0.27 ^EUR	-.--%

Current month	-60.87%
1 month	-65.82%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/400/0.1/18.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-28	0.27	-.--%
24-06-27	0.27	-.--%
24-06-26	0.27	-.--%
24-06-25	0.27	-12.90%
24-06-24	0.31	-13.89%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 03:40 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC9M0Y
ISIN	DE000HC9M0Y2
Date issued	2023-10-02
Strike	400 $
Maturity	2024-09-18 (80 Days)
Parity	10 : 1
Emission price	5.9 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	6.48 €
Lowest since issue	0.21 €
Delta	-0.1x
Omega	13.87
Premium	15.4x
Gearing	134.65x
Moneyness	0.8534
Difference Strike	-68.72 $
Difference Strike %	-17.18%
Spread	0.07 €
Spread %	19.44%
Theoretical value	0.3250
Implied Volatility	30.11 %
Total Loss Probability	86.93 %
Intrinsic value	0.000000
Present value	0.3250
Break even	396.52 €
Theta	-0.04x
Vega	0.04x
Rho	-0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

468.7 USD

Average target price

468.3 USD

Spread / Average Target

-0.10%

Consensus